Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Quentin M Anstee

Showing results (211-220 of 262) with videos related to

Pageof 27
Sort By:
Liver Cancer|January 2, 2023
Sulfatase-2 from Cancer Associated Fibroblasts: An Environmental Target for Hepatocellular Carcinoma?Marco Y W Zaki, Sari F Alhasan, Ruchi Shukla, et al.
Journal of Hepatology|November 28, 2020
Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scoresCristiana Bianco, Oveis Jamialahmadi, Serena Pelusi, et al.
Cancer Medicine|July 6, 2017
Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver diseaseBenedetta Donati, Alessandro Pietrelli, Piero Pingitore, et al.
Hepatology (Baltimore, Md.)|September 26, 2024
Letter to the Editor: Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)Mazen Noureddin, Emily Truong, Rebeca Mayo, et al.
Hepatology (Baltimore, Md.)|July 28, 2023
Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)Mazen Noureddin, Emily Truong, Rebeca Mayo, et al.
Journal of Hepatology|December 13, 2021
The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?Jeffrey V Lazarus, Henry E Mark, Marcela Villota-Rivas, et al.
The New England Journal of Medicine|October 20, 2021
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASHSven M Francque, Pierre Bedossa, Vlad Ratziu, et al.
Hepatology (Baltimore, Md.)|May 10, 2023
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM studyQuentin M Anstee, Kathryn J Lucas, Sven Francque, et al.
Science Translational Medicine|October 20, 2021
Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensorsSophie C Cazanave, Andrew D Warren, Maciej Pacula, et al.
Journal of Hepatology|March 10, 2020
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trialsStephen A Harrison, Vincent Wai-Sun Wong, Takeshi Okanoue, et al.
Pageof 27

Showing results (211-220 of 262) with videos related to

Sort By:
Pageof 27
Liver Cancer|January 2, 2023
Sulfatase-2 from Cancer Associated Fibroblasts: An Environmental Target for Hepatocellular Carcinoma?Marco Y W Zaki, Sari F Alhasan, Ruchi Shukla, et al.
Journal of Hepatology|November 28, 2020
Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scoresCristiana Bianco, Oveis Jamialahmadi, Serena Pelusi, et al.
Cancer Medicine|July 6, 2017
Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver diseaseBenedetta Donati, Alessandro Pietrelli, Piero Pingitore, et al.
Hepatology (Baltimore, Md.)|September 26, 2024
Letter to the Editor: Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)Mazen Noureddin, Emily Truong, Rebeca Mayo, et al.
Hepatology (Baltimore, Md.)|July 28, 2023
Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)Mazen Noureddin, Emily Truong, Rebeca Mayo, et al.
Journal of Hepatology|December 13, 2021
The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?Jeffrey V Lazarus, Henry E Mark, Marcela Villota-Rivas, et al.
The New England Journal of Medicine|October 20, 2021
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASHSven M Francque, Pierre Bedossa, Vlad Ratziu, et al.
Hepatology (Baltimore, Md.)|May 10, 2023
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM studyQuentin M Anstee, Kathryn J Lucas, Sven Francque, et al.
Science Translational Medicine|October 20, 2021
Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensorsSophie C Cazanave, Andrew D Warren, Maciej Pacula, et al.
Journal of Hepatology|March 10, 2020
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trialsStephen A Harrison, Vincent Wai-Sun Wong, Takeshi Okanoue, et al.
Pageof 27